Effect of Pioglitazone on the Course of New Onset Type 1 Diabetes Mellitus - Full Text View

Purpose

A study to examine the effect of pioglitazone on the course of new onset type 1 diabetes mellitus.

Condition	Intervention	Phase
Type 1 Diabetes Mellitus	Drug: pioglitazone Drug: Placebo control	Phase I

MedlinePlus related topics:

Diabetes Diabetes Type 1

ChemIDplus related topics:

Insulin Pioglitazone Pioglitazone hydrochloride

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study

Official Title:	Effect of Pioglitazone on the Course of New Onset Type 1 Diabetes Mellitus

Further study details as provided by Stony Brook University:

Primary Outcome Measures:

C-peptide response to a Sustacal meal [ Time Frame: 6 months ]

Secondary Outcome Measures:

Insulin requirement [ Time Frame: 6 months ]
Hemoglobin A1c [ Time Frame: 6 months ]

Arms	Assigned Interventions
Pioglitazone: Experimental	Drug: pioglitazone
Placebo control: Placebo Comparator	Drug: Placebo control

Detailed Description:

Thiazolidinediones have been shown to reduce the development of diabetes mellitus in animal models of type 1 diabetes and to reduce the death of beta cells (cells that make insulin) in petri dishes. Pioglitazone is a thiazolidinedione currently approved for the treatment of type 2 diabetes. This study explores the question of whether pioglitazone can preserve beta cell function in patients with recently diagnosed type 1 diabetes mellitus.

Eligibility

Ages Eligible for Study:	6 Years to 18 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients with type 1 diabetes mellitus diagnosed within 4 months
Age > 6 years of age
Ability to swallow capsule
Signed informed consent / assent

Exclusion Criteria:

Other illnesses

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00545857

Contacts


Contact: Thomas` A Wilson, MD	631 689-9703	Thomas.A.Wilson@SUNYSB.EDU

Locations


United States, New York
	GCRC / Stony Brook University Hospital	Recruiting
	Stony Brook, New York, United States, 11794-8111
	Principal Investigator: Thomas A Wilson, MD
	Sub-Investigator: Andrew H. Lane, MD

Sponsors and Collaborators

Stony Brook University

Investigators


Principal Investigator:	Thomas A Wilson, MD	State University of New York, Stony Brook

More Information

Study ID Numbers:	20064114
First Received:	October 16, 2007
Last Updated:	October 16, 2007
ClinicalTrials.gov Identifier:	NCT00545857
Health Authority:	United States: Institutional Review Board

Keywords provided by Stony Brook University:

Type 1 diabetes

Insulin dependent diabetes

Juvenile onset diabetes

pioglitazone

Study placed in the following topic categories:

Autoimmune Diseases

Pioglitazone

Diabetes Mellitus, Type 1

Diabetes Mellitus

Endocrinopathy

Metabolic disorder

Glucose Metabolism Disorders

Insulin

Additional relevant MeSH terms:

Hypoglycemic Agents

Metabolic Diseases

Immune System Diseases

Physiological Effects of Drugs

Endocrine System Diseases

Pharmacologic Actions

ClinicalTrials.gov processed this record on July 03, 2008

Sponsored by:	Stony Brook University
Information provided by:	Stony Brook University
ClinicalTrials.gov Identifier:	NCT00545857